CDK9 inhibitor
Kronos Bio Slashes Staff by 19% to Fund Upcoming Solid Tumor Trial
Anika Sharma
Kronos Bio is undergoing a strategic reorganization, including a staff reduction of 19%, following promising early trial results for a ...
Kronos Bio is undergoing a strategic reorganization, including a staff reduction of 19%, following promising early trial results for a ...